Page last updated: 2024-11-07

bis(2-(n-phenylcarboxamido)phenyl)diselenide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

bis(2-(N-phenylcarboxamido)phenyl)diselenide: selenoorganic cpd which has mitogenic activity in human peripheral leukocytes [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129387
CHEMBL ID385817
SCHEMBL ID10520791
MeSH IDM0185314

Synonyms (17)

Synonym
n-phenyl-2-[[2-(phenylcarbamoyl)phenyl]diselanyl]benzamide
106663-84-7
benzamide, 2,2'-(1,2-diselanediyl)bis[n-phenyl-
nsc-639778
nsc639778
bpcpds
ebselen diselenide
CHEMBL385817
benzamide, 2,2'-diselenobis(n-phenyl-
diebs
bis(2-(n-phenylcarboxamido)phenyl)diselenide
2,2-diselenobis(n-phenylbenzamide)
SCHEMBL10520791
DTXSID10147718
[2-(n-phenyl-carboxamido)phenyl] diselenide
bdbm50197347
2,2'-diselanediylbis(n-phenylbenzamide)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Urease subunit alphaHelicobacter pylori 26695IC50 (µMol)35.82500.29003.87606.7000AID1632342; AID1632343; AID1632344; AID1632345
Urease subunit alphaHelicobacter pylori 26695Ki0.65100.22603.40579.3400AID1632341
Methionine aminopeptidase 2Homo sapiens (human)IC50 (µMol)0.23000.00060.96835.6000AID1322288
Urease subunit betaHelicobacter pylori 26695IC50 (µMol)35.82500.29003.87606.7000AID1632342; AID1632343; AID1632344; AID1632345
Urease subunit betaHelicobacter pylori 26695Ki0.65100.22603.40579.3400AID1632341
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
protein processingMethionine aminopeptidase 2Homo sapiens (human)
peptidyl-methionine modificationMethionine aminopeptidase 2Homo sapiens (human)
N-terminal protein amino acid modificationMethionine aminopeptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
RNA bindingMethionine aminopeptidase 2Homo sapiens (human)
aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
initiator methionyl aminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
protein bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloexopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
metal ion bindingMethionine aminopeptidase 2Homo sapiens (human)
metalloaminopeptidase activityMethionine aminopeptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
cytosolMethionine aminopeptidase 2Homo sapiens (human)
plasma membraneMethionine aminopeptidase 2Homo sapiens (human)
cytoplasmMethionine aminopeptidase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1322289Inhibition of human APN at <2 mM using AMC-labeled substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
AID1632339Steady state inhibition of Sporosarcina pasteurii CCM 2056 urease using urea as substrate assessed as inhibition constant for final enzyme conformation-inhibitor complex by measuring ammonia levels after 120 mins by phenol-hypochlorite method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1632340Competitive reversible inhibition of recombinant Helicobacter pylori urease infected in transformed Escherichia coli rosetta DE3 after 120 mins by Lineweaver-Burk plot analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1632343Inhibition of recombinant Helicobacter pylori urease expressed in Escherichia coli rosetta DE3 using urea as substrate assessed as transformed cell urea splitting activity preincubated for 2 hrs followed by substrate addition measured after 2 hrs by Berth2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID274136Inhibition of gamma radiation-induced lipid peroxidation in liposomes at 200 uM2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1632344Inhibition of urease in Helicobacter pylori J99 in Brucella broth using urea as substrate after 2 hrs by Berthelot assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID274138Effect on gamma irradiation-induced TBARS formation in liposomes at 50 uM2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1632338Reversible inhibition of Sporosarcina pasteurii CCM 2056 urease using urea as substrate assessed as ammonia levels after 120 mins by fast dilution assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1632342Inhibition of recombinant Helicobacter pylori urease expressed in Escherichia coli rosetta DE3 using urea as substrate assessed as transformed cell urea splitting activity after 2 hrs by Berthelot assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID274137Inhibition of horseradish peroxidase by spectrophotometric method2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1632345Inhibition of urease in Helicobacter pylori J99 in Brucella broth using urea as substrate preincubated for 2 hrs followed by substrate addition measured after 2 hrs by Berthelot assay2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1322290Inhibition of pig APN at <2 mM using AMC-labeled substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
AID274141Antioxidant activity assessed by singlet oxygen quenching ability at 1mM2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Horseradish peroxidase inhibition and antioxidant activity of ebselen and related organoselenium compounds.
AID1632337Competitive inhibition of Sporosarcina pasteurii CCM 2056 urease using urea as substrate assessed as ammonia levels after 120 mins by Lineweaver-Burk plot analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1322288Non-covalent/mixed type inhibition of recombinant human MetAP2 using Met-AMC as substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
AID1632341Inhibition of recombinant Helicobacter pylori urease expressed in Escherichia coli rosetta DE3 after 120 mins by Berthelot colorimetric analysis2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
1,2-Benzisoselenazol-3(2H)-one Derivatives As a New Class of Bacterial Urease Inhibitors.
AID1322291Inhibition of pig LAP at <2 mM using AMC-labeled substrate preincubated for 30 mins followed by substrate addition by spectrofluorimetric method2016Bioorganic & medicinal chemistry letters, 11-01, Volume: 26, Issue:21
Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's4 (33.33)18.2507
2000's5 (41.67)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.88 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]